Evidence map›Paper›PMID 35075934›Full record

Trial reportIntegrative cancer therapies

Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With Active Hexose-correlated Compound Derived From Lentinula edodes Mycelia.

Toshiya Kamiyama, Tatsuya Orimo, Kenji Wakayama, Tatsuhiko Kakisaka, Shingo Shimada, Akihisa Nagatsu, Yoh Asahi, Takeshi Aiyama, Hirofumi Kamachi, Akinobu Taketomi

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. The Health and Clinical Benefits of Medicinal Fungi.Advances in biochemical engineering/biotechnology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Toshiya KamiyamaHokkaido University Graduate School of Medicine, Sapporo, Japan.ORCID 0000-0002-9157-7811
Tatsuya OrimoHokkaido University Graduate School of Medicine, Sapporo, Japan.
Kenji WakayamaHokkaido University Graduate School of Medicine, Sapporo, Japan.
Tatsuhiko KakisakaHokkaido University Graduate School of Medicine, Sapporo, Japan.
Shingo ShimadaHokkaido University Graduate School of Medicine, Sapporo, Japan.
Akihisa NagatsuHokkaido University Graduate School of Medicine, Sapporo, Japan.
Yoh AsahiHokkaido University Graduate School of Medicine, Sapporo, Japan.ORCID 0000-0002-0985-7874
Takeshi AiyamaHokkaido University Graduate School of Medicine, Sapporo, Japan.ORCID 0000-0001-5658-2730
Hirofumi KamachiHokkaido University Graduate School of Medicine, Sapporo, Japan.
Akinobu TaketomiHokkaido University Graduate School of Medicine, Sapporo, Japan.
Hokkaido University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeActive hexose-correlated compound (AHCC), a standardized extract of cultured Lentinula edodes mycelia, exerts antitumor effects through anti-inflammatory and immune-modulatory functions. Adjuvant therapy for patients with hepatocellular carcinoma (HCC) who have undergone curative hepatectomy has not been established. The purpose of this study was to evaluate the efficacy and safety of AHCC as adjuvant therapy in patients with advanced HCC after curative hepatectomy. PATIENTS AND

methodsThe study design was single-armed, non-randomized, open (no one was blinded), and uncontrolled. Patients with HCC who underwent curative hepatectomy were treated with AHCC (1 g) 3 times daily orally for 2 years. The inclusion criteria were HCC diagnosed preoperatively as stages A and B of the Barcelona clinic liver cancer (BCLC) classification and alpha-fetoprotein × protein induced by vitamin K absence or antagonist II (PIVKA-II) ≥ 10

resultsA total of 29 patients were treated with AHCC, of which 25 (4 patients discontinued) were followed up. The 2-year recurrence-free survival rate after resection was 48% for those without discontinuations and 55.2% for all patients with a history of treatment. Serum albumin levels decreased to a minimum in the first postoperative month and gradually recovered to the preoperative level at 6 months. Almost no change in lymphocyte percentage was observed during follow-up. Inflammation-based prognostic scores were maintained at favorable levels after hepatectomy. Toxicity and adverse events were not observed in any patient.

conclusionAHCC may be safe and effective in preventing HCC recurrence after curative hepatectomy, and further randomized trials of AHCC for its use in this setting are warranted.This clinical trial was registered in UMIN Clinical Trials Registry (ID UMIN000024396).

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsShiitake MushroomsHepatectomyHexosesHumansNeoplasm Recurrence, LocalPrognosisRetrospective StudiesHexosesadjuvantAHCChepatectomyhepatocellular carcinomarecurrence

Identifiers

PMID35075934
PMCPMC8793419
OpenAlexW4210331232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.